Related Experiment Video
Updated: Apr 19, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.7K
Spesolimab for generalized pustular psoriasis: A prospective study with a 6-month-follow-up
Emna Bahloul1, Kmar Turki1, Mariem Nouri2
1Dermatology department, Hedi Chaker University Hospital, Sfax, Tunisia.
Clinical and Experimental Dermatology
|April 18, 2026
Summary
Spesolimab effectively treated generalized pustular psoriasis (GPP) flares in a real-world setting, showing rapid improvement and good tolerability. Treatment outcomes were similar regardless of IL36RN mutation status, though long-term maintenance requires further study.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Generalized pustular psoriasis (GPP) is a severe, life-threatening dermatosis.
- Limited real-world data exist for spesolimab, an anti-interleukin-36 receptor (IL-36R) therapy.
Purpose of the Study:
- To assess the real-world effectiveness and safety of spesolimab in GPP patients.
- To investigate the impact of IL36RN mutation status on spesolimab treatment response.
Main Methods:
- Prospective study of 14 GPP patients receiving a single intravenous infusion of spesolimab.
- Disease severity assessed via GPPASI score at multiple follow-up points.
- IL36RN c.80T>C (p.L27P) mutation screening using Sanger sequencing.
Main Results:
- Significant GPPASI score reduction observed from baseline, persisting for 3 months.
- Rapid clinical improvement noted by day 7, with sustained response in most patients.
- No significant difference in response based on IL36RN mutation status; no adverse events reported.
Conclusions:
- Spesolimab shows rapid efficacy and excellent tolerability for GPP flares.
- Treatment benefits are independent of IL36RN mutation status.
- Further research is needed to optimize long-term and maintenance strategies for GPP.
